Research Topics
Species | Tarja KokkolaSummaryAffiliation: University of Kuopio Country: Finland Publications
| Collaborators |
Detail Information
Publications
Important amino acids for the function of the human MT1 melatonin receptorTarja Kokkola
Department of Physiology, University of Kuopio, 70211, Kuopio, Finland
Biochem Pharmacol 65:1463-71. 2003..Several important amino acids for the human MT1 melatonin receptor function were revealed in the current study, with effects of mutations ranging from slightly reduced affinity or efficacy to complete loss of function...
S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific mannerTarja Kokkola
Department of Physiology, University of Kuopio, POB 1627, FIN 70211, Kuopio, Finland
BMC Cell Biol 6:21. 2005....
The functional role of cysteines adjacent to the NRY motif of the human MT1 melatonin receptorTarja Kokkola
Department of Physiology, University of Kuopio, Kuopio, Finland
J Pineal Res 39:1-11. 2005..Taken together, these data show that the two conserved cysteines in the end of transmembrane domain III of the MT1 melatonin receptor, especially C130 (Cys(3.55)), are needed for normal G protein activation and receptor trafficking...
Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulationTarja Kokkola
Institute of Biomedicine Physiology, University of Kuopio, Kuopio, Finland
J Pineal Res 43:255-62. 2007..Luzindole also stimulates downregulation of the MT1 receptor protein, interfering with the synthesis and/or degradation of the receptor...
Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptorJuha R Savinainen
Department of Physiology, University of Kuopio, POB 1627, FIN 70211 Kuopio, Finland
Br J Pharmacol 145:636-45. 2005..WIN55212-3 offers a valuable tool for further characterization of ligand activities at the CB(2) receptor and may serve as a lead compound in further efforts to develop more potent and selective neutral CB(2) receptor antagonists...
